skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Yttrium Y 90 Basiliximab (Code C99167)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Yttrium Y 90 Basiliximab

Definition: A radioimmunoconjugate composed of basiliximab, a chimeric, mouse-human monoclonal antibody directed against the alpha subunit of interleukin-2 receptor (IL-2R alpha, CD25 or Tac antigen), and labeled with yttrium y 90, with potential antineoplastic activity. The basiliximab moiety of yttrium Y 90 basiliximab selectively binds to IL-2R alpha expressed on the surface of activated T-lymphocytes, thereby preventing IL-2 binding and blocking the IL-2-mediated activation of lymphocytes. The yttrium y 90 moiety selectively delivers a cytotoxic dose of beta radiation to lymphocytes that express the IL-2 receptor. This may prevent T cell-mediated activation of the immune system against a certain transplant and may prevent transplant rejection.

Display Name: Yttrium Y 90 Basiliximab

Label: Yttrium Y 90 Basiliximab

NCI Thesaurus Code: C99167 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL433016  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
90Y Basiliximab
Yttrium Y 90 Basiliximab

External Source Codes: 
PDQ Closed Trial Search ID 717514
PDQ Open Trial Search ID 717514 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C99167
Contributing_Source CTRP
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom